Oxford, UK, 27 May 2025 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company harnessing the power of non-coding human genetics to discover first-in-class antibody treatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business Officer with immediate effect. Read more…
The catastrophic fall from grace of the genetic testing app 23 and Me is a salutary lesson for all companies that espouse the use of “big data” in healthcare. Once a leading digital health tech firm, worth $6 billion as recently as 2021, the company is now on the verge of being taken private at […]
By Stephen Adams, Optimum Strategic Communications Nature has been an inspiration behind the development of many drugs, starting with the humble aspirin, which was originally derived from willow bark. But what if we could learn the secrets of what gives some people the incredible ability to overcome the most serious diseases? What if we could […]
Cambridge, UK, 20th October 2022: Enhanc3D Genomics (“Enhanc3D”), a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, today announces it has raised £10 million in Series A financing to accelerate the development of its proprietary technology platform – “GenLink3DTM”. The financing was led by BGF and Parkwalk Advisors, […]
